New tool may predict kidney cancer drug success
NCT ID NCT02848768
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a prediction tool (nomogram) to see if it could forecast how patients with metastatic clear cell renal cell carcinoma respond to the targeted therapy sunitinib. Researchers looked at 45 patients who had their kidney removed and were treated with sunitinib as their first therapy. The goal was to identify who would be resistant or respond well, potentially guiding better treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sunitinib
What this could lead to
If successful, this tool could help doctors predict which patients will benefit from sunitinib and which may need alternative treatments.
What could go wrong
This is a small, completed study that only validates a prediction model. It does not test a new treatment, and the tool may not be accurate for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Rennes
Rennes, 35033, France